Lipocine Inc. Appoints Michael Grissinger to Compensation Committee

What Happened
Lipocine Inc. (LPCN) filed a Form 8-K disclosing that on August 18, 2026 its Board of Directors appointed Michael Grissinger to serve as a member of the Board’s Compensation Committee. The company reported Mr. Grissinger is eligible to receive an additional $7,500 per year for his service on the committee.

Key Details

• Appointment date: August 18, 2026.
• Role: Member of Lipocine’s Compensation Committee of the Board of Directors.
• Compensation: Eligible for an additional $7,500 per year for committee service.
• Disclosure filed on Form 8-K (filed August 21, 2026).

Why It Matters
This filing documents a governance change related to oversight of executive pay and compensation policies. For investors, committee membership updates are relevant because the Compensation Committee helps set and review executive and director pay; the disclosed $7,500 annual stipend is a modest, specific change in director compensation. There were no other officer departures or additional arrangements reported in this filing.